Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Monod Bio is raising $26,250,876.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Daniel Manzano played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Monod Bio

Monod Bio is a pioneer company in the design of de novo protein biosensors. Our innovative biosensor platform technology takes advantage of the most recent advances in computational protein engineering to create highly modular biosensing nanoswitches that enable rapid, sensitive, and inexpensive analytical assays. Our visionary founding team and state-of-the-art technology position Monod Bio at the forefront of biosensor innovation, and we welcome exceptional individuals to join us in this journey.

To learn more about Monod Bio, visit http://www.monod.bio/

Contact:
Daniel Manzano, Chief Executive Officer
206-822-1255
daniel@monod.bio

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved